Skip to content

Study · Observational study · n = 98 · 2026

8 results

Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.

Kuckuck S, van Gerwen N, Oosterman JE, Savas M, Kavousi M, Penninx BWJH, Boon MR, van Rossum EFC

Diabetes, obesity & metabolism5 Jan 2026Cited by 1 (Europe PMC)

PMID41491619 (opens in a new tab)PMCIDPMC12890760 (opens in a new tab)DOI10.1111/dom.70393 (opens in a new tab)PepBankPUB-41491619
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with obesity, liraglutide treatment was associated with lower body weight after 4 months.

    In plain wordsIn people with obesity, body weight fell after 4 months of liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 98

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 4 monthsAs given in this study (human).

    Measurements

    Body weight change
    −5.8%
    after 4 months

    Source sentences

    Summary
    Body weight decreased after 4 months (-5.8%, p < 0.001).
    1 context sentence
    Summary · context
    We included 98 patients with obesity treated with liraglutide 3.0 mg. The Hospital Anxiety and Depression Scale (HADS: total score 0-42; depression/anxiety subscales 0-21), OBESI-Q psychological wellbeing (0-100) and anthropometrics were assessed at baseline and 4-month follow-up.
  2. 02HumanObservational studyEfficacy outcome

    In patients with obesity, liraglutide treatment was associated with a lower HADS total score after 4 months.

    In plain wordsIn people with obesity, overall anxiety and depression scores fell after liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHADS total score
    Study

    n = 98

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.0 mg · 4 monthsAs given in this study (human).

    Measurements

    HADS total score change
    −1.7
    after 4 months

    Source sentences

    Summary
    HADS total, depression, and (in trend) anxiety scores slightly decreased (-1.7 [95% confidence interval [CI] -3.2; -0.1, p < 0.05]; -1.0 [95% CI: -1.9; -0.1, p < 0.05] and -0.7 [95% CI: -1.5; 0.1, p = 0.095]).
    1 context sentence
    Summary · context
    We included 98 patients with obesity treated with liraglutide 3.0 mg. The Hospital Anxiety and Depression Scale (HADS: total score 0-42; depression/anxiety subscales 0-21), OBESI-Q psychological wellbeing (0-100) and anthropometrics were assessed at baseline and 4-month follow-up.
  3. 03HumanObservational studyEfficacy outcome

    In patients with obesity, liraglutide treatment was associated with a lower HADS depression score after 4 months.

    In plain wordsIn people with obesity, depression scores fell after liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHADS depression score
    Study

    n = 98

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.0 mg · 4 monthsAs given in this study (human).

    Measurements

    HADS depression score change
    −1
    after 4 months

    Source sentences

    Summary
    HADS total, depression, and (in trend) anxiety scores slightly decreased (-1.7 [95% confidence interval [CI] -3.2; -0.1, p < 0.05]; -1.0 [95% CI: -1.9; -0.1, p < 0.05] and -0.7 [95% CI: -1.5; 0.1, p = 0.095]).
    1 context sentence
    Summary · context
    We included 98 patients with obesity treated with liraglutide 3.0 mg. The Hospital Anxiety and Depression Scale (HADS: total score 0-42; depression/anxiety subscales 0-21), OBESI-Q psychological wellbeing (0-100) and anthropometrics were assessed at baseline and 4-month follow-up.
  4. 04HumanObservational studyEfficacy outcome

    In patients with obesity, liraglutide treatment was associated with a nonsignificant trend toward a lower HADS anxiety score after 4 months (change -0.7, 95% CI -1.5 to 0.1; P = 0.095).

    In plain wordsIn people with obesity, anxiety scores showed a nonsignificant downward trend after liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    No significant changeHADS anxiety score
    Study

    n = 98

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.0 mg · 4 monthsAs given in this study (human).

    Measurements

    HADS anxiety score change
    −0.7
    after 4 months

    Source sentences

    Summary
    HADS total, depression, and (in trend) anxiety scores slightly decreased (-1.7 [95% confidence interval [CI] -3.2; -0.1, p < 0.05]; -1.0 [95% CI: -1.9; -0.1, p < 0.05] and -0.7 [95% CI: -1.5; 0.1, p = 0.095]).
    1 context sentence
    Summary · context
    We included 98 patients with obesity treated with liraglutide 3.0 mg. The Hospital Anxiety and Depression Scale (HADS: total score 0-42; depression/anxiety subscales 0-21), OBESI-Q psychological wellbeing (0-100) and anthropometrics were assessed at baseline and 4-month follow-up.
  5. 05HumanObservational studyEfficacy outcome

    In patients with obesity, liraglutide treatment was associated with increased OBESI-Q psychological wellbeing after 4 months.

    In plain wordsIn people with obesity, psychological wellbeing scores increased after liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    IncreaseOBESI-Q psychological wellbeing
    Study

    n = 98

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.0 mg · 4 monthsAs given in this study (human).

    Measurements

    OBESI-Q psychological wellbeing score change
    4.3
    after 4 months

    Source sentences

    Summary
    OBESI-Q psychological wellbeing scores increased (4.3 [95% CI: 0.8; 7.8, p < 0.05]).
    1 context sentence
    Summary · context
    We included 98 patients with obesity treated with liraglutide 3.0 mg. The Hospital Anxiety and Depression Scale (HADS: total score 0-42; depression/anxiety subscales 0-21), OBESI-Q psychological wellbeing (0-100) and anthropometrics were assessed at baseline and 4-month follow-up.
  6. 06HumanObservational studyEfficacy outcome

    In patients with obesity, weight loss after liraglutide treatment occurred regardless of initial mental health.

    In plain wordsAfter liraglutide treatment, people with obesity lost weight regardless of starting mental health.

    Peptide
    Liraglutide
    Outcome
    Not applicableWeight loss by baseline mental health
    Study

    n = 98

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Weight loss occurred regardless of initial mental health.
    1 context sentence
    Summary · context
    We included 98 patients with obesity treated with liraglutide 3.0 mg. The Hospital Anxiety and Depression Scale (HADS: total score 0-42; depression/anxiety subscales 0-21), OBESI-Q psychological wellbeing (0-100) and anthropometrics were assessed at baseline and 4-month follow-up.
  7. 07HumanObservational studyOther

    In patients with obesity treated with liraglutide, anthropometric changes were associated with mental health and psychological wellbeing changes, either significantly or as a trend.

    In plain wordsIn people with obesity after liraglutide treatment, body-measurement changes were linked to mental health and wellbeing changes, significantly or as a trend.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedAnthropometric and mental health changes
    Study

    n = 98

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.0 mg · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Anthropometrics changes were associated with changes in mental health and psychological wellbeing either significantly or in trend.
    1 context sentence
    Summary · context
    We included 98 patients with obesity treated with liraglutide 3.0 mg. The Hospital Anxiety and Depression Scale (HADS: total score 0-42; depression/anxiety subscales 0-21), OBESI-Q psychological wellbeing (0-100) and anthropometrics were assessed at baseline and 4-month follow-up.
  8. 08HumanObservational studyEfficacy outcome

    In patients with obesity, mental health improvements after liraglutide treatment occurred mainly in those with poor baseline mental health.

    In plain wordsAfter liraglutide treatment, mental health improvements in people with obesity occurred mainly among those with poorer baseline mental health.

    Peptide
    Liraglutide
    Outcome
    IncreaseMental health by baseline status
    Study

    n: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.0 mg · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Mental health improvements occurred mainly in patients with poor baseline mental health.
    1 context sentence
    Summary · context
    We included 98 patients with obesity treated with liraglutide 3.0 mg. The Hospital Anxiety and Depression Scale (HADS: total score 0-42; depression/anxiety subscales 0-21), OBESI-Q psychological wellbeing (0-100) and anthropometrics were assessed at baseline and 4-month follow-up.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.